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Abstract: Antiplatelet agents are the cornerstone of treatment for patients with acute coronary 
syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Clopidogrel, when 
added to aspirin, has demonstrated considerable success at reducing thrombotic complications 
of ACS and/or PCI compared to aspirin alone and is standard of care for the management 
of patients with ACS and in patients undergoing PCI. Prasugrel is a novel thienopyridine 
antiplatelet agent recently approved for the treatment of patients with ACS undergoing PCI. 
Prasugrel provides greater and more consistent platelet inhibition than clopidogrel due to earlier 
and more extensive formation of its active metabolite. The enhanced platelet inhibition with 
prasugrel led to a reduction in major adverse cardiovascular events in patients with moderate 
to high risk ACS scheduled for PCI in the phase 3 TRITON-TIMI 38 trial. This benefit was 
seen more in patients suffering a STEMI and those with diabetes. However, this reduction in 
events was met with a significant increase in the risk of bleeding which overcame prasugrel’s 
benefit in certain groups. Future studies with prasugrel are needed to determine its optimal 
utilization to minimize bleeding risks and evaluate its outcomes in ACS and safety profile in 
special patient populations.
Keywords: clopidogrel, prasugrel, percutaneous coronary intervention, acute coronary 
syndrome
Introduction to the use and development  
of antiplatelet agents
There is an evolving emphasis on optimizing antiplatelet therapy in the treat-
ment of vascular disease and in patients undergoing vascular procedures. Plate-
lets play an important role in cardiovascular disease both in the pathogenesis 
of atherosclerosis and in the development of acute thrombotic events.1 Their 
importance in vascular disease is indirectly confirmed by the benefit of antiplatelet 
agents in these disorders. Antiplatelet agents are the cornerstone of treatment for 
patients with acute coronary syndrome (ACS) undergoing percutaneous coronary 
intervention (PCI).2
For many years, aspirin has been the mainstay of antiplatelet drug therapy in 
vascular disease. As an antiplatelet agent, aspirin has been shown to greatly reduce 
major vascular adverse events.3 Its benefit has been linked to its ability to 
permanently acetylate cyclooxygenase 1 (COX-1), preventing the conversion 
of arachidonic acid to thromboxane A2 by the platelet. Thromboxane A2 is a 
strong platelet agonist and inhibiting its production decreases overall platelet 
aggregation at the site of the vascular injury. However, blocking this pathway Vascular Health and Risk Management 2009:5 874
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has a limited overall effect on the various pathways 
of platelet activation. While aspirin markedly reduces 
arachidonic acid-induced platelet aggregation, platelet 
reactivity mediated by COX-1 independent pathways 
(ie, collagen and adenosine diphosphate) can remain 
high.4,5 The need for inhibition of other platelet activa-
tion pathways has led to the development of additional 
antiplatelet drugs.
Adenosine diphosphate (ADP) is recognized as 
one of the most important mediators of both physi-
ologic hemostasis and thrombosis.6–10 Development and 
utilization of the thienopyridines, agents that block ADP 
receptors on the platelet membrane, has represented 
a major advancement for treatment of patients with 
ACS undergoing PCI. The thienopyridines were the 
first alternative to aspirin for platelet inhibition. Since 
they inhibit platelets by different mechanisms, aspirin 
and thienopyridines work synergistically and are best 
when used in combination. Clopidogrel, when added 
to aspirin, has demonstrated considerable success at 
reducing thrombotic complications of ACS and/or PCI 
compared to aspirin alone.11 Despite clopidogrel’s ability 
to effectively prevent myocardial infarction (MI), stroke 
or death in patients with ACS and those undergoing PCI, 
it has limitations that compromise its clinical utility: 
delayed onset of action, modest platelet inhibition and 
variability in patients’ responses.12 These issues might 
explain why some patients continue to suffer from major 
adverse cardiovascular events while receiving dual oral 
antiplatelet therapy. Both the success and inadequacy 
of clopidogrel has prompted the search for similar but 
superior antiplatelet agents with more rapid onset of 
action and less patient variability.
Prasugrel is a novel antiplatelet agent that recently 
received Food and Drug Administration (FDA) approval for 
the treatment of patients with ACS undergoing PCI. Prasu-
grel is a thienopyridine with a chemical structure (Figure 1) 
and mechanism of action similar to that of clopidogrel. 
This review focuses on the pharmacologic and therapeutic 
differences between prasugrel and clopidogrel.
Review of pharmacology, mode 
of action, pharmacokinetics 
of prasugrel, comparison 
to clopidogrel
Administered orally, the thienopyridines are normally rapidly 
and extensively absorbed. Clopidogrel absorption is limited 
by the drug efflux transporter, P-glycoprotein (encoded by the 
ABCB1 gene). Polymorphisms of the ABCB1 gene contribute 
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to the wide interpatient variability of clopidogrel bioavailability. 
Prasugrel’s solubility decreases with increasing gastric pH. 
Proton pump inhibitors (PPIs) increase gastric pH, slowing 
the rate of dissolution and absorption of a prasugrel dose.13 
However, this does not reduce the prasugrel’s antiplatelet 
response. Clopidogrel absorption appears to be unaffected by 
PPIs, however its antiplatelet effect is reduced by the PPIs’ 
effect on clopidogrel metabolism. H2 blockers do not affect 
either the absorption of either prasugrel or clopidogrel.14
The thienopyridines are prodrugs that must be metabo-
lized in vivo into active form. Both prasugrel and clopidogrel 
require CYP450 metabolism for the generation of active 
metabolites, but the pathways leading to conversion to the 
active metabolites differ between the prodrugs (Figure 1). 
The majority of clopidogrel is metabolized into inactive 
metabolites by de-esterification. The remaining 15% of 
clopidogrel is converted to its active metabolite by 2 CYP-
dependent steps (Figure 1). CYP1A2, CYP3A4/5, CYP2C9 
and CYP2C19 are considered to be the main contributors to 
active metabolite formation.15–18 Prasugrel is rapidly hydro-
lyzed by intestinal hydroxyesterases to an inactive thiolactone 
(R-95913), which is metabolized to the active metabolite, 
R-138727 by a single step, primarily by CYP3A4 and 
CYP2B6, and to a lesser extent by CYP2C9 and CYP2C19 
(Figure 1).19 CYP3 A is considered the major enzyme respon-
sible for active metabolite formation. Prasugrel metabolism 
is extensive as parent drug cannot be detected in plasma. 
The active metabolite is detected in human plasma within 
15 minutes of administration and reaches maximum plasma 
concentration at approximately 30 minutes.20–22 The active 
metabolite R-138727 has an elimination half life of about 
7.4 hours (range 2 to 15 hours).22 Unbound active metabo-
lite is subsequently metabolized to inactive compounds 
by S-methylation (R-106583) and by cysteine conjugation 
(R-119251).22 The inactive metabolites are then primarily 
excreted in the urine.22
The  need  for  bioactivation  by  CYPs  puts  the 
thienopyridines at risk for drug interactions with CYP 
inhibitors and inducers. Clopidogrel’s active metabolite 
production and antiplatelet response are reduced by 
CYP3A4 and CYP2C19 inhibitors.21,23,24 Alternatively, 
St John’s wort and rifampin, CYP3A4 inducers increase 
clopidogrel’s antiplatelet response.24,25 In incubations of 
human liver microsomes, CYP3A4 inhibition with keto-
conazole and CYP2B6 inhibition by monoclonal antibody 
significantly reduced prasugrel active metabolite formation.19 
However, when tested in vivo, only the rate of active metabo-
lism formation was reduced by ketoconazole, however there 
was no change in AUC.21 Thus, the interaction between 
prasugrel and CYP3A4 inhibitors appears not to be of clinical 
significance. In addition, no significant interaction was found 
between the CYP3A4 inducer rifampin and prasugrel.26 
Inhibition of CYP2C19 and CYP2C9 have only minor effects 
on prasugrel metabolism.19
Genetic variation in the CYPs is an important determinant 
in clopidogrel active metabolite formation and antiplatelet 
response. Particularly, carriers of a reduced-function 
CYP2C19 allele have significantly lower levels of the active 
metabolite of clopidogrel, diminished platelet inhibition, 
and a higher rate of major adverse cardiovascular events.27,28 
In healthy subjects and patients with stable atherosclerosis 
and ACS, genetic variation in CYP3A5, CYP2B6, CYP2C9, 
or CYP2C19 has no clinically significant effect on prasugrel 
as defined by active metabolite exposure levels.29–31
The active metabolites of prasugrel and clopidogrel 
produce their antiplatelet effect by irreversible inhibition of 
the platelet P2Y12 receptor. The P2Y12 receptor is responsible 
for the completion of ADP-induced platelet aggregation, 
augments platelet aggregation by other platelet agonists, 
such as collagen, thrombin, serotonin, epinephrine, and 
TxA2, and also amplifies the other functional consequences 
of activation, including granule release, TxA2 formation, and 
platelet proinflammatory and procoagulant activity.6–9 Several 
laboratory tests can be used to measure the thienopyridine 
effects on platelet activation and aggregation. In general, three 
methods are used to evaluate the pharmacodynamic response 
to the thienopyridines: light transmittance aggregometry 
(LTA), the VerifyNow P2Y12 assay, and the vasodilator-
stimulated phosphoprotein (VASP) phosphorylation assay 
by flow cytometry. With LTA, ADP is used to stimulate 
platelet-rich plasma. Inhibition of platelet aggregation (IPA) 
is calculated as the percent decrease in aggregation during 
treatment when compared with baseline.32–35 There is no con-
sensus definition for classifying antiplatelet response using 
this test. The VerifyNow P2Y12 assay is a point-of-care light 
transmittance assay which uses whole blood.36–38 This test is 
more specific than LTA for P2Y12 inhibition, as prostaglandin 
E1 is used to suppress the platelet P2Y1 receptor response 
to ADP. The assay allows detection of absolute platelet 
reactive units (PRU) values and percent P2Y12 receptor 
inhibition, which can be calculated as a percent change 
from baseline platelet aggregation. VASP phosphorylation 
is a test that directly measures the function of the P2Y12 
receptor.39 Dephosphorylation of VASP occurs following 
P2Y12 stimulation. Levels of VASP phosphorylation/
dephosphorylation thus reflect P2Y12 inhibition/activation. Vascular Health and Risk Management 2009:5 876
Norgard and Abu-Fadel Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
VASP phosphorylation provides a selective index of platelet 
inhibition by the thienopyridines (platelet reactivity index 
[PRI]) and is not affected by other commonly used plate-
let inhibitors such as aspirin. Based on previous studies, 
patients are regarded as good responders to clopidogrel if 
PRI is  50% and poor responders if PRI is  50%. Both in 
healthy subjects and coronary artery disease patients, there is 
a good agreement of antiplatelet response to thienopyridines 
measured by ADP-induced LTA, the VerifyNow P2Y12 assay, 
and VASP phosphorylation.39–42
Several studies have demonstrated that a poor response 
to clopidogrel, defined as failure of the drug to achieve the 
expected suppression of platelet function as measured by 
any of the mentioned laboratory tests, identifies patients 
at risk of adverse clinical outcomes during treatment with 
clopidogrel.32,43–45 The pharmacodynamic response to clopi-
dogrel varies widely from subject to subject. Clopidogrel 
has been shown to produce 5% platelet inhibition in some 
patients and up to 90% platelet inhibition in others with 
a roughly normal distribution.46 Approximately 30% of 
patients exhibit low platelet inhibition from clopidogrel are 
at risk for worsened cardiovascular outcomes.47,48 There are 
numerous mechanisms for a poor response to clopidogrel in 
patients, as genetic, metabolic, cellular, and clinical factors 
have been proposed. Higher doses of clopidogrel have been 
used to overcome hyporesponsiveness.49–56 While the mean 
platelet inhibition is greater with higher doses, significant 
interpatient variability remains and not all clopidogrel 
hyporesponsiveness can be overcome.49–56 Prasugrel was 
developed to produce a greater and more consistent platelet 
inhibition than clopidogrel.
Several studies have compared the platelet inhibitory 
capacity of prasugrel and clopidogrel. Preclinical studies 
indicate that prasugrel is approximately 10-fold more potent 
than clopidogrel at inhibiting platelet aggregation, inhibiting 
thrombus formation, and prolonging bleeding times.57–59 
In clinical studies, prasugrel has consistently demonstrated 
greater and more rapid platelet inhibition than clopidogrel 
in healthy subjects, patients with stable coronary artery 
disease (CAD) and acute coronary syndromes, and those 
undergoing PCI. In addition, subjects who are poor responders 
to clopidogrel respond adequately to prasugrel.20,60,61 Loading 
doses of prasugrel, 30 mg to 75 mg, produce a dose-dependent 
platelet inhibition from 57% up to 90% inhibition of platelet 
aggregation.57,58 Prasugrel loading doses of 20, 30, 40, and 
60 mg have been shown to generate greater inhibition of 
platelet aggregation compared to a 300-mg clopidogrel 
loading dose.20,62–65 A 60-mg prasugrel loading dose was 
shown to cause greater platelet inhibition when compared 
head-to-head with a 600-mg clopidogrel loading dose.65,66 
Along with a greater magnitude of platelet inhibition, prasugrel 
has a more rapid onset of platelet inhibition. Maximal effects 
of a 300-mg dose of clopidogrel are seen 6 hours after 
administration. A 600-mg dose of clopidogrel achieves 
maximal inhibition 2 to 4 hours after administration. After a 
60-mg dose of prasugrel, onset of platelet inhibition is seen 
after 15 minutes and reaches maximal effect after ∼1 hour. 
Maintenance doses of 5, 10, and 15 mg prasugrel also achieve 
consistent and significantly greater platelet inhibition than 
the standard 75-mg clopidogrel maintenance dose.62,63,65,66 
A 10-mg prasugrel maintenance dose was shown to cause 
greater platelet inhibition when compared head-to-head with 
a 150-mg clopidogrel maintenance dose.64 Changing from 
clopidogrel therapy to prasugrel maintenance therapy results 
in further reductions in maximal ADP-induced platelet aggre-
gation early after switching.67
The antiplatelet effects of the active metabolites of 
prasugrel and clopidogrel are about equally potent in vitro.68 
Subjects who are poor responders to clopidogrel have lower 
exposure to the active metabolite of clopidogrel than subjects 
who are normal responders.69 This implies that prasugrel’s 
greater pharmacodynamic effect is related to the earlier 
and more extensive formation of the active metabolite of 
prasugrel compared with the equipotent active metabolite 
of clopidogrel.
Efficacy and comparative studies 
with clopidogrel
Prasugrel has been tested for efficacy in multiple studies. Three 
major clinical trials led to the approval of its use clinically. The 
Joint Utilization of Medications to Block Platelets Optimally 
(JUMBO-TIMI 26) was a phase 2, dose ranging, and safety trial 
of prasugrel vs clopidogrel in 904 patients undergoing elective 
or urgent PCI. After diagnostic angiography, patients were 
randomized to either clopidogrel (300 mg loading dose [LD] 
followed by 75 mg daily) or to 1 of 3 doses of prasugrel, a low-
dose regimen 40 mg LD plus 7.5 mg daily, an intermediate-dose 
regimen 60 mg LD plus 10 mg daily, or a high-dose regimen 60 
mg LD plus 15 mg daily. Patients were treated with the study 
drug maintenance dose for 1 month with the co-administration 
of aspirin 325 mg daily. The study found no significant differ-
ence in non-CABG bleeding between those receiving prasugrel 
and clopidogrel at 30 days (prasugrel 1.7% vs clopidogrel 1.2%) 
or in TIMI major and minor bleeding. However, more TIMI 
minor bleeding events were detected in the prasugrel high-dose 
regimen group (3.6%) compared to the intermediate-(1.5%) or Vascular Health and Risk Management 2009:5 877
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low-dose regimen (2.0%) groups and to the clopidogrel group 
(2.4%). The trial also showed a numerically lower incidence of 
major adverse cardiac events at 30 days in the prasugrel-treated 
patients, a difference that did not achieve statistical significance 
as a secondary efficacy end point.70
An additional evaluation of prasugrel vs clopidogrel was 
done in the The Prasugrel in Comparison to Clopidogrel 
for Inhibition of Platelet Activation and Aggregation 
(PRINCIPLE-TIMI 44) study in which 201 patients were ran-
domized in a double-blind, two-phase crossover of prasugrel vs 
high-dose clopidogrel for planned PCI. During the first phase, 
prasugrel 60 mg loading dose was compared to clopidogrel 600 
mg loading dose with a primary end point of platelet inhibition 
at 6 hours. In the second phase, patients received 10 mg mainte-
nance dose of prasugrel for 14 days vs 150 mg clopidogrel after 
the initial loading dose. On day 15 the patients were crossed 
over to the alternate maintenance treatment for an additional 2 
weeks. As for the results, the IPA at 6 hours was significantly 
higher in the prasugrel group (74.8% ± 13% vs 31.8% ± 
21.1%). The enhanced inhibitory effect of prasugrel was seen 
as early as 30 minutes after the loading dose. Patients treated 
with prasugrel also had more consistent levels of inhibition 
with significantly lower interpatient variability. In addition, 
the IPA after a 2 week maintenance dose was significantly 
greater in the prasugrel (61.3% ± 17.8% vs 46.1% ± 21.3%). 
Of importance, prasugrel was well tolerated and only 2 patients 
in this group (none in the clopidogrel group) had TIMI minor 
bleeding before the cross over. The data from the PRINCIPLE-
TIMI 44 confirmed that prasugrel is a more potent inhibitor 
of platelet aggregation in the setting of scheduled PCI. It also 
showed its ability to yield a rapid, high and consistent level 
of platelet inhibition. However, the question remained: Does 
a more potent platelet inhibition translate into a reduction in 
the atherothrombotic events clinically?
The Trial to Assess Improvement in Therapeutic 
Outcomes  by  Optimizing  Platelet  Inhibition  with 
Prasugrel (TRITON)-TIMI 38 was a phase 3, randomized, 
double-blind, parallel group, multinational, clinical study 
designed to address this question and to evaluate for the first 
time in a large-scale clinical study whether a thienopyridine 
that results in a higher IPA results in improved clinical 
outcomes and is safe to use compared to the standard 
use of clopidogrel.71 The trial randomly assigned 13,608 
patients with moderate to high risk ACS including 10,074 
patients with unstable angina (UA) or non-ST segment 
elevation myocardial infarction (NSTEMI) and 3,534 
patients with STEMI scheduled for PCI on a background 
of ASA therapy to clopidogrel 300 mg loading and 
75 mg maintenance vs prasugrel 60 mg loading and 10 mg 
maintenance. The loading dose was given any time between 
randomization and 1 hour after leaving the catheterization 
lab. Of importance is that the coronary anatomy had to be 
known to be suitable for PCI prior to randomization in all 
cases. Study subjects were followed at hospital discharge, 
30 days, 90 days and at 3-month intervals for a total of 6 to 
15 months. Key exclusion criteria included increased risk 
of bleeding, anemia, thrombocytopenia, known intracranial 
abnormalities, or the use of thienopyridines in the last 5 days. 
PCI at the time of randomization was performed on 99% of 
patients and 94% received at least one intracoronary stent. 
Drug eluting stents were used in 47% of subjects.
The primary efficacy end point for the study was a com-
posite of the rate of cardiovascular death, nonfatal MI or 
non-fatal stroke during the follow-up period. This occurred 
in 781 patients (12.1%) receiving clopidogrel compared to 
643 patients (9.9%) receiving prasugrel (hazard ratio [HR] 
for prasugrel vs clopidogrel 0.81; 95% CI 0.73 to 0.90; 
P  0.001). This translates to a number needed to treat (NNT) 
of forty-five. A significant benefit from prasugrel was seen by 
the first prespecified end point at 3 days (HR 0.82; CI, 0.71 
to 0.96; P = 0.01).72 In addition this benefit persisted through 
out the follow up period, which suggest a continued benefit of 
greater IPA during maintenance therapy after steady state IPA 
was achieved. Benefit was seen across the ACS spectrum. 
When patients were stratified by the presenting diagnosis, 
patients with UA and NSTEMI showed significant benefit 
with prasugrel compared to clopidogrel (HR 0.82; 95% CI 
0.73 to 0.93; P = 0.002). An analysis of patients with STEMI 
(n = 3534) also showed a significant reduction in events 
with prasugrel at 30 days (HR 0.68; 95% CI 0.54 to 0.87; 
P = 0.0017) and at 15 months (HR 0.79; 95% CI 0.65 to 0.97; 
P = 0.02).73 There is some concern regarding the superiority 
of prasugrel due to the substantial inclusion of extra adjudi-
cated MIs on top of investigator-reported MIs which resulted 
in an increase in the total reported primary outcomes.74 
The clinical relevance of these ‘extra MIs’ is questionable. 
Additionally, the inclusion of these extra adjudicated events 
doubled the benefit of prasugrel over clopidogrel and are 
needed for maintain statistical significance.
The benefit of prasugrel, with regard to the primary end 
point, was seen both with and without the use of glycoprotein 
IIb/IIIa antagonists during the index hospitalization.75 The 
benefit with prasugrel vs clopidogrel tended to be greater 
among the 3,146 patients with diabetes (HR 0.70; 95% CI, 
0.58 to 0.85; P  0.001) as compared to non diabetics (HR 
0.86; 95% CI, 0.76–0.98; P = 0.02).76 The prasugrel group Vascular Health and Risk Management 2009:5 878
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also showed a significant reduction in the secondary end 
point of death from cardiovascular causes, nonfatal MI, or 
urgent target vessel revascularization at 30 days (HR 0.78; 
95% CI 0.69 to 0.89; P  0.001) and 90 days (HR 0.79; 
95% CI 0.70 to 0.90; P  0.001), as well as in the end point 
of death from cardiovascular causes, nonfatal MI, nonfatal 
stroke, or rehospitalization for ischemia (HR 0.84; 95% CI 
0.76 to 0.92; P  0.001). Significant reductions were seen 
in the prasugrel group compared with the clopidogrel group 
in the rates of MI (9.5% vs 7.3%; HR 0.76; 95% CI 0.67 
to 0.85; P  0.001), urgent target-vessel revascularization 
(3.7% vs 2.5%; HR 0.66; 95% CI 0.54 to 0.81; P  0.001), 
and stent thrombosis (2.4% vs 1.1%; HR 0.48; 95% CI 0.36 
to 0.64; P  0.001). The findings on stent thrombosis were 
statistically significant irrespective of stent type.77
In a follow up study to TRITON-TIMI 38, Murphy et al 
hypothesized that prasugrel would reduce not only first 
events but also recurrent primary endpoint events and total 
events as compared to clopidogrel.78 This study is important 
since in the TRITON trial patients who experienced a com-
ponent of the primary endpoint were censored from analysis 
following the initial event. Even though these patients con-
tinue to be followed during the trial, any additional events 
they have are generally not included in the primary endpoint 
efficacy analysis. This is important since in a real world set-
ting these events are important for both the patient and the 
treating physician. In this analysis it was noted that patients 
with multiple events were older, had more co-morbidities at 
study entry including hypertension and diabetes and tended 
to be more females than males. Of importance, patients 
randomized to prasugrel were slightly older, less likely to be 
diabetic and more likely to have had multivessel PCI. Results 
of this analysis showed that among patients with an initial 
non-fatal event, second events were significantly reduced 
with prasugrel compared to clopidogrel (10.8 vs 15.4%; 
HR 0.65; 95% CI 0.46 to 0.92; P = 0.016), as was CV death 
following the non-fatal event (3.7 vs 7.1%; HR 0.46; 95% 
CI 0.25 to 0.82; P = 0.008). Overall, there was a reduction 
of 195 total primary efficacy events with prasugrel vs clopi-
dogrel (rate ratio 0.79; 95% CI 0.71 to 0.87; P  0.001). The 
reduction in second events with prasugrel was consistent in 
several key subgroups, including the elderly, gender, stent 
type, index event, and creatinine clearance. There was also a 
larger risk reduction in subsequent events in diabetics treated 
with prasugrel. These findings suggest that continued therapy 
with a regimen that provides higher levels of IPA remains 
important, even after an ischemic event has occurred. Indeed, 
intensive anti-platelet therapy seems to be of added benefit 
to those who have already had such an event. Based on the 
observation that total number of events in this analysis was 
higher with clopidogrel, it is possible that those patients 
with recurrent events may be more resistant to anti-platelet 
therapy, and/or more likely to be hyporesponders to platelet 
inhibition, which is associated with an increased risk of 
thrombotic events.77
Safety and tolerability of prasugrel 
and clopidogrel
The greater efficacy of prasugrel and its higher level of IPA 
come with a price. The most notable safety issue linked to the 
thienopyridines is their tendency to cause bleeding. Earlier 
studies showed signs of prasugrel’s increased bleeding 
potential.70 The large TRITON-TIMI 38 study provided 
more conclusive evidence that prasugrel is associated with 
excess bleeding relative to clopidogrel, irrespective of 
bleeding definition, seriousness, or location, and across most 
subgroups assessed.71 Among patients treated with prasugrel 
in the study, 146 (2.4%) had TIMI major bleeding that was 
not related to coronary artery bypass grafting (CABG)as 
compared to 111 patients (1.8%) treated with clopidogrel 
(HR 1.32; 95% CI 1.03 to 1.68; number needed to harm 
[NNH] = 167; P = 0.03). This included a higher rate of 
life-threatening bleeding episodes. Additionally, in patients 
undergoing CABG, there was a significantly higher rate of 
bleeding in the prasugrel group (13.4% vs 3.2%; NNH = 10). 
Thus, prasugrel should not be the drug of choice for patients 
in whom CABG surgery is anticipated or cannot be ruled out 
because the coronary anatomy is unknown. Fatal TIMI major 
bleeding occurred in a significantly higher number of patients 
treated with prasugrel (0.4% vs 0.1%; P = 0.002). Intracranial 
bleeding was similar in both groups and occurred at a rate of 
0.3% per group. It is interesting to note that approximately 
one-third of all bleeding events were recorded in the first 
day and almost half of all bleeding events were reported 
in the initial 10 days. Although bleeding can cause serious 
morbidity and mortality, the most critical consequences 
of bleeding (death, MI, and stroke), were included in the 
primary efficacy endpoint, where prasugrel was superior 
to clopidogrel. In addition, in a prespecified analysis of net 
clinical benefit, which included rates of efficacy endpoints 
and bleeding endpoints, prasugrel was noted to be superior 
to clopidogrel (12.2% vs 13.9%; P = 0.004).73
The TRITON authors identified a few patient subgroups 
that did not have a net clinical outcome with prasugrel.71 These 
subgroups included patients with previous stroke or transient 
ischemic attacks (TIAs), patients 75 years of age or older, Vascular Health and Risk Management 2009:5 879
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and patients weighing less than 60 kg. These 3 subgroups 
had no clinical benefit from prasugrel mainly due to higher 
risk of bleeding with the drug. In particular, prasugrel’s risk 
of bleeding in patients over 75 was similar to that in younger 
patients, however the outcomes secondary to bleeding in 
prasugrel-treated patients over 75 years of age were more 
serious in nature. Bleeding events in older patients were 
more often fatal or symptomatic intracranial hemorrhage. 
As prasugrel’s efficacy is less clear in this subgroup of 
patients and appear to be at risk of more serious bleeding 
events, use of prasugrel should be discouraged in patients 
75 years of age. Patients without any of these risk factors 
had a greater efficacy with prasugrel without a significant 
difference in the rate of major bleeding and thus a substan-
tially favorable net clinical benefit for the use of prasugrel. 
However, until additional work is done to better define the 
risks and benefits, the use of prasugrel should be avoided in 
patients with previous stroke/TIAs, age over 75, or weight 
under 60 kg.
As for the tolerability of prasugrel, more patients treated 
with prasugrel had to discontinue the drug due to adverse 
events related to bleeding compared to clopidogrel (2.5% vs 
1.4%). As for adverse events not related to bleeding in the 
TRITON study, 4.7% of patients treated with prasugrel and 
5.0% of clopidogrel treated patients had to stop the drugs 
(P = 0.37) mainly due to severe thrombocytopenia (0.3% 
in both groups), neutropenia which was significantly higher 
in the clopidogrel group (0.1% vs 0.2%), and colonic 
neoplasms due to increased diagnosis after GI bleeding in 
most of these patients which was significantly higher in the 
prasugrel group (0.2% vs 0.1%; P = 0.03)(9).
Conclusion
Prasugrel represents an advance in oral antiplatelet therapy 
for patients with ACS treated with PCI. Clopidogrel, when 
added to aspirin, has been successful at reducing thrombotic 
complications of PCI and has been considered standard of 
care for several years. However, there are patients that remain 
at risk despite clopidogrel therapy, partly due to an inadequate 
pharmacodynamic response to the drug. Prasugrel, compared 
to clopidogrel, significantly decreases the risk for MI and 
stent thrombosis in patients with ACS undergoing PCI. 
This benefit was seen more in patients suffering a STEMI 
and those with diabetes. On the other hand, this reduction 
in events was met with a significant increase in the risk of 
bleeding. Prasugrel’s benefit and risk are related to greater 
inhibition of platelet aggregation. Although excess fatal 
and non-fatal bleeding in prasugrel patients is obviously 
undesirable, it does not seem to outweigh prasugrel’s benefit. 
The exception is in patients over the age of 75, weight under 
60 kg, and patients with a history of stroke or TIA. Prasugrel 
should be avoided in these patients. Future studies will deter-
mine whether lower prasugrel doses can be used to reduce 
bleeding risk while maintaining clinical efficacy.
Compared to clopidogrel, prasugrel’s scope of use is 
relatively limited. It is indicated for use in patients undergoing 
PCI for ACS, but only for those in whom the coronary 
anatomy is known and CABG is unlikely. The use of prasu-
grel upstream in the emergency room is not recommended 
because of the high potential for CABG related bleeding. 
This should not influence outcome in patients who undergo 
PCI quickly after presentation. What about patients that are 
delayed in going for PCI? We know that upstream initiation 
of clopidogrel is advantageous as it shows benefit within 24 
hours of initiation.79,80 It is still unknown whether withhold-
ing prasugrel treatment until PCI has negative consequences 
when the procedure is delayed. There is also no indication for 
its use in elective PCI and stable CAD. Future studies are still 
needed to define further the optimal use of prasugrel.
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